close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

32.14 -0.32 (-0.99%)
Streaming Delayed Price Updated: 3:01 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations For Viridian Therapeutics's Future ↗
 
Via Benzinga
News headline image
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics ↗
 
Via Benzinga
News headline image
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease ↗
The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked. 
Via Investor's Business Daily
News headline image
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Decoding 6 Analyst Evaluations For Viridian Therapeutics ↗
 
Via Benzinga
News headline image
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival ↗
The results are also promising for the next-generation version of that drug. 
Via Investor's Business Daily
News headline image
Viridian Therapeutics Discloses 'Exciting' Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety ↗
Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans... 
Via Benzinga
News headline image
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗
VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Top 3 Health Care Stocks You May Want To Dump This Quarter ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today